WO1991001740A1 - Process for producing pharmacosmetics - Google Patents
Process for producing pharmacosmetics Download PDFInfo
- Publication number
- WO1991001740A1 WO1991001740A1 PCT/HU1989/000039 HU8900039W WO9101740A1 WO 1991001740 A1 WO1991001740 A1 WO 1991001740A1 HU 8900039 W HU8900039 W HU 8900039W WO 9101740 A1 WO9101740 A1 WO 9101740A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- ointment
- pharmacosmetics
- producing
- toxin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 239000002674 ointment Substances 0.000 claims abstract description 13
- 239000003053 toxin Substances 0.000 claims abstract description 9
- 231100000765 toxin Toxicity 0.000 claims abstract description 9
- 239000013543 active substance Substances 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims abstract description 4
- 239000007900 aqueous suspension Substances 0.000 claims abstract description 4
- 239000003998 snake venom Substances 0.000 claims abstract description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 8
- 229960001047 methyl salicylate Drugs 0.000 description 4
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 3
- 241000271537 Crotalus atrox Species 0.000 description 3
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002435 venom Substances 0.000 description 3
- 231100000611 venom Toxicity 0.000 description 3
- 210000001048 venom Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000272074 Bungarus Species 0.000 description 1
- 241000271533 Crotalus durissus terrificus Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002821 viper venom Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
Definitions
- the object of the invention is a process for producing pharmacosmetics comprising snake-venom.
- the venom of Crotalus atrox is a complex active substance which has analgetic, hyperaemizating and spasmolysant activity at the same time and may be used for both therapeutic and veterinary purposes.
- the compositions known from the literature do not dispose of such a complex and multiple activity.
- composition produced by the process of the invention comprises thus the - preferably lyophilized - venom of Crotalus atrox as active substance, in a quantity of 0,0002 to 0,1 % as compared to the total amount of the composition, processed into ointment, aqueous suspension, emulsive composition, gel-formed composition, etc., with usual additives and/or auxiliaries.
- the toxin Crotali atrocis is a light yellow, odourless powderj identity: dissolved in 1 mg of water and dropped on filter-paper with ninhydrin it discolours at a slight heat effect.
- the composition is for external used in case of rheumatism, arthritis, arthrosis, ischias, lumbago, muscular aches occurring after sport achievements, and the like.
- the production of the composition comprises - if processed for example as ointment - mixing methylsalicylate and camphoric acid at room temperature.
- the lyophilized toxin Crotali atrocis is dissolved in distilled water, then mixed with methylsalicylate in a homogenizer of high speed of revolutions.
- the aqueous toxin solution is added dropwise, the substance is then homogenized for 4 hours at least.
- the suspension is added to a mass of ointment Unguenta composita (a mixture of equal proportion of polyoxetene 400 and polyoxetene 1540) and is homogenized for 6 to 8 hours at room temperature.
- Unguenta composita a mixture of equal proportion of polyoxetene 400 and polyoxetene 1540
- composition produced by the process of the invention is illustrated by the following non-limiting examples.
- camphoric acid 3 0 g
- toxin 1000 ⁇ g of toxin at the most, but preferably 50 ⁇ g of toxin are used.
- the components are mixed according to the technology referred to above.
- the ointment contains 5 to 20 % by mass of water and detergent may also be used.
- the manufacturing technology is modified, i.e. the camphoric acid and methylsalicylate are mixed with 0,1-2,0 % of detergent, e.g. with Tween 20 or Ka-laurylsulfate.
- conserving agents such as Sol. conservans may be added to the ointment, in a quantity of 0,1-0,5 % by mass.
- aqueous suspension is produced.
- Unguenta composita is replaced by ethyl alcohol in a concentration of 30-80 % by mass.
- Emulsive composition is prepared by using sunflower oil instead of Unguenta composita and shaking up before use is stipulated in the instructions for use, or sunflower oil is used only in Unguenta composita instead of polyoxetene 1540.
- Gel-formed composition is obtained if instead of polyoxetene 1540 3 % by mass of aqueous solution of hydroxymethylcellulose is used.
- a stick of 3-4 cm of ointment is expressed on the skin surface and massaged by fine medico-massage on the aching spot (joint) for 5-10 minutes morning and evening, for six days.
- the treatment is repeated 3-4 times.
- the ointment cannot be used on skinless surfaces.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a method of producing pharmacosmetics comprising snake-venom. The method of the invention comprises processing the - preferably lyophilized - toxin Crotali atrocis as active substance, in a quantity of 0,0002 - 0,1 % as compared to the total amount of the composition, into ointment, aqueous suspension, emulsive composition, gel-formed composition and the like with usual additives and/or auxiliaries.
Description
PROCESS FOR PRODUCING PHARMACOSMETICS
Technical Field
The object of the invention is a process for producing pharmacosmetics comprising snake-venom.
Background Art
It is well known that the Soviet pharmaceutical industry produces and markets an ointment under the trade name Viprosal, the active ingredient of which is viper venom.
For veterinary purposes the venom of a snake belonging to Bungarus genus, of cobra (Kaja genus) and of Crotalus terrificus - differing from the species Crotalus atrox - has been used. These solutions are disclosed in patent specifications GB 1 446 234, US 4 027 012, 4 126 676 and 4 232 308.
Disclosure of the Invention
It has been found that the venom of Crotalus atrox is a complex active substance which has analgetic, hyperaemizating and spasmolysant activity at the same time and may be used for both therapeutic and veterinary purposes. The compositions known from the literature do not dispose of such a complex and multiple activity.
The composition produced by the process of the invention comprises thus the - preferably lyophilized - venom of Crotalus atrox as active substance, in a quantity of 0,0002 to 0,1 % as compared to the total amount of the composition, processed into ointment, aqueous suspension, emulsive composition, gel-formed composition, etc., with usual additives and/or auxiliaries.
The toxin Crotali atrocis is a light yellow, odourless powderj identity: dissolved in 1 mg of water and dropped on filter-paper with ninhydrin it discolours at a slight heat effect.
Determination of contents: nitrogen content 11,5 % at least according to Ph.Hg.VII (Hungarian Pharmacopoeia).
The composition is for external used in case of rheumatism, arthritis, arthrosis, ischias, lumbago, muscular aches
occurring after sport achievements, and the like.
The production of the composition comprises - if processed for example as ointment - mixing methylsalicylate and camphoric acid at room temperature. The lyophilized toxin Crotali atrocis is dissolved in distilled water, then mixed with methylsalicylate in a homogenizer of high speed of revolutions. The aqueous toxin solution is added dropwise, the substance is then homogenized for 4 hours at least. The suspension is added to a mass of ointment Unguenta composita (a mixture of equal proportion of polyoxetene 400 and polyoxetene 1540) and is homogenized for 6 to 8 hours at room temperature. The obtained composition may be stored in dry, cool place for 5 years without decomposition.
Best Mode of Carrying out the Invention
The composition produced by the process of the invention is illustrated by the following non-limiting examples.
Example 1 (ointment)
The following components are mixed according to the technology described above:
Toxin Crotali atrocis sice. 0,001 g
methylsalicylate 6,0 g
camphoric acid 3,0 g
Unguenta composita ad 100,0 g
Example 2 (ointment)
In case of tubes of 50 g 10μg of toxin at the least,
1000 μg of toxin at the most, but preferably 50μg of toxin are used.
The components are mixed according to the technology referred to above.
In addition to the active substance, the ointment contains 5 to 20 % by mass of water and detergent may also be used.
In this case the manufacturing technology is modified, i.e. the camphoric acid and methylsalicylate are mixed with
0,1-2,0 % of detergent, e.g. with Tween 20 or Ka-laurylsulfate.
As additive, conserving agents, such as Sol. conservans may be added to the ointment, in a quantity of 0,1-0,5 % by mass.
Example 3
Instead of ointment, aqueous suspension is produced. In the formula of Example 1, Unguenta composita is replaced by ethyl alcohol in a concentration of 30-80 % by mass.
Example 4
Emulsive composition is prepared by using sunflower oil instead of Unguenta composita and shaking up before use is stipulated in the instructions for use, or sunflower oil is used only in Unguenta composita instead of polyoxetene 1540.
Example 5
Gel-formed composition is obtained if instead of polyoxetene 1540 3 % by mass of aqueous solution of hydroxymethylcellulose is used.
During the application for example a stick of 3-4 cm of ointment is expressed on the skin surface and massaged by fine medico-massage on the aching spot (joint) for 5-10 minutes morning and evening, for six days.
At one week intervals the treatment is repeated 3-4 times.
The ointment cannot be used on skinless surfaces.
Claims
C L A I M :
Process for producing pharmacosmetics comprising snake-venom, c h a r a c t e r i z e d i n that the - preferably lyophilized - toxin Crotali atrocis is processed as active substance, in a quantity of 0,0002 - 0,1 as compared to the total amount of the composition, into ointment, aqueous suspension, emulsive composition, gel-formed composition and the like with usual additives and/or auxiliaries.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/HU1989/000039 WO1991001740A1 (en) | 1989-08-05 | 1989-08-05 | Process for producing pharmacosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/HU1989/000039 WO1991001740A1 (en) | 1989-08-05 | 1989-08-05 | Process for producing pharmacosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1991001740A1 true WO1991001740A1 (en) | 1991-02-21 |
Family
ID=10980844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/HU1989/000039 WO1991001740A1 (en) | 1989-08-05 | 1989-08-05 | Process for producing pharmacosmetics |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1991001740A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085391A1 (en) * | 2001-04-24 | 2002-10-31 | Luis Alberto Costa | Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids |
| US6555109B1 (en) | 1998-01-20 | 2003-04-29 | S.I.S. Shulov Institute For Science Ltd. | Analgesic from snake venom |
| US7208150B1 (en) | 1999-07-14 | 2007-04-24 | S.I.S. Shulov Institute For Science Ltd. | Analgesic from snake venom |
| EP1765851A4 (en) * | 2004-05-06 | 2008-05-28 | Laboratorios Biosintetica Ltda | ANALOGUE COMPOUNDS OF ANALGESIC PEPTIDES DERIVED FROM THE VENICE OF CROSSALUS DURRIQUE TERRIFICUS SNAKES, THEIR APPLICATIONS, COMPOSITIONS AND METHODS FOR THE PREPARATION AND PURIFICATION OF THESE COMPOUNDS |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3639796A1 (en) * | 1985-11-22 | 1987-07-09 | Oncogen | GROWTH-PREVENTING SNAKE POISIDE PEPTIDE |
-
1989
- 1989-08-05 WO PCT/HU1989/000039 patent/WO1991001740A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3639796A1 (en) * | 1985-11-22 | 1987-07-09 | Oncogen | GROWTH-PREVENTING SNAKE POISIDE PEPTIDE |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555109B1 (en) | 1998-01-20 | 2003-04-29 | S.I.S. Shulov Institute For Science Ltd. | Analgesic from snake venom |
| US7208150B1 (en) | 1999-07-14 | 2007-04-24 | S.I.S. Shulov Institute For Science Ltd. | Analgesic from snake venom |
| WO2002085391A1 (en) * | 2001-04-24 | 2002-10-31 | Luis Alberto Costa | Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids |
| EP1765851A4 (en) * | 2004-05-06 | 2008-05-28 | Laboratorios Biosintetica Ltda | ANALOGUE COMPOUNDS OF ANALGESIC PEPTIDES DERIVED FROM THE VENICE OF CROSSALUS DURRIQUE TERRIFICUS SNAKES, THEIR APPLICATIONS, COMPOSITIONS AND METHODS FOR THE PREPARATION AND PURIFICATION OF THESE COMPOUNDS |
| US9109041B2 (en) | 2004-05-06 | 2015-08-18 | Yara Cury | Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0098743B1 (en) | Phenyl alpha-acyloxyacetamide derivates and their therapeutic use | |
| HUT67436A (en) | Process to prepare novel hydroxamic acid and n-hydroxyurea derivatives and pharmaceutical compn.s contg. them | |
| DE69704426D1 (en) | METHOD FOR PRODUCING MEDICAL CHEWING GUM WITH A GOOD TASTE, INCLUDING AN INCLUDING COMPOUND | |
| RU93004907A (en) | Hydroxamic Acid Derivatives and N-Hydroxyurea. METHOD FOR PRODUCING THE PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT | |
| NO179995C (en) | Process for the preparation of low-toxicity drug-lipid systems containing polyene antibiotics | |
| DK390587A (en) | 7-OEOE3-AMINOMETHYL-3-ALKYLAA-1-PYRROLIDINYLAA-QUINO LIN-CARBOXYLIC ACID | |
| KR870700599A (en) | Carboxylic acid derivatives, methods for their preparation, pharmaceutical compositions containing these compounds and uses thereof | |
| RU95111308A (en) | Derivatives of 2-amino-4-phenyl-4-oxobutyric acid, methods of synthesis, pharmaceutical composition | |
| DE69705414D1 (en) | PURE, BIOLOGICALLY ACTIVE COLISTIN, ITS INGREDIENTS AND A COLISTIN PREPARATION FOR THE TREATMENT OF INFLAMMATORY RESPIRATION | |
| RU95100189A (en) | Method of antiinflammatory ointment preparing | |
| DE69825733T2 (en) | SPECIFIC INHIBITORS OF PANCREATIC LIPASE AND ITS APPLICATIONS | |
| WO1991001740A1 (en) | Process for producing pharmacosmetics | |
| ATE3552T1 (en) | PROCESS FOR THE PREPARATION OF PHOSPHONO-HYDROXY-ACETIC ACID AND SALTS THEREOF AND AUTIVIRALS CONTAINING THEM. | |
| US6696419B1 (en) | Boron compounds and complexes as anti-inflammatory agents | |
| ATE40793T1 (en) | PHARMACEUTICAL PREPARATION FOR THERAPEUTIC TREATMENT OF RHEUMATIC DISEASES. | |
| ES8705434A1 (en) | PROCEDURE FOR THE PREPARATION OF ACID DERIVATIVES 4- (ISOXAZOLIL) -TIAZOL-2-OXAMICO | |
| DK527186D0 (en) | SOURCE CHODILATING PHARMACEUTICAL PREPARATION | |
| RU2091065C1 (en) | Ointment for psoriasis treatment | |
| US6288047B1 (en) | Lipid-based immune modulator composition | |
| Demirci et al. | In vivo inhibition of inducible nitric oxide and evaluation of the brain tissue damage induced by Toxocara canis larvae in experimentally infected mice | |
| FR2580648B1 (en) | NOVEL TRIAZOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| FR2384791A1 (en) | NEW EVERNINOMICINE DERIVATIVES, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAID DERIVATIVES | |
| HU913009D0 (en) | Method for producing inhibitors of calcium ingestion | |
| IT8024165A0 (en) | ESTERS OF DIALOGENOVINILCICLOPROPANCARBOXYLIC ACIDS, PROCEDURE FOR THEIR PREPARATION AND THEIR USE TO FIGHT HARMFUL ORGANISMS AND ALSO ALPHA-HALOGENETHYL-3-PHENOXYBENZYL ALCOHOL. | |
| EP1233772A1 (en) | Boron compounds and complexes as anti-inflammatory agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP NO US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |